Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary
disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving
some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that
has shown promise in improving cardiovascular outcomes in similar populations. Thus the
purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.